Other News To Note
Thursday, March 22, 2012
Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, received orphan drug designation from the FDA for its candidate for carcinoid syndrome, telotristat etiprate (LX1032). Lexicon reported positive Phase II results in August 2011 and is preparing a global Phase III development plan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.